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ABSTRACT
Lung adenosquamous carcinoma is a particular subtype of non-small cell lung 
carcinoma that is defined by the coexistence of adenocarcinoma and squamous cell 
carcinoma components. The aim of this study was to assess the mutational profile 
in each component of 16 adenosquamous carcinoma samples from a Caucasian 
population by a combination of next generation sequencing using the cancer hotspot 
panel as well as the colon and lung cancer panel and FISH. Identified mutations were 
confirmed by Sanger sequencing of DNA from cancer cells of each component collected 
by Laser Capture microdissection. Mutations typical for adenocarcinoma as well as 
squamous cell carcinoma were identified. Driver mutations were predominantly in the 
trunk suggesting a monoclonal origin of adenosquamous carcinoma. Most remarkably, 
EGFR mutations and mutations in the PI3K signaling pathway, which accounted for 
30% and 25% of tumors respectively, were more prevalent while KRAS mutations 
were less prevalent than expected for a Caucasian population. Surprisingly, expression 
of classifier miR-205 was intermediate between that of classical adenocarcinoma and 
squamous cell carcinoma suggesting that adenosquamous carcinoma is a transitional 
stage between these tumor types. The high prevalence of therapy-relevant targets 
opens new options of therapeutic intervention for adenosquamous carcinoma patients.
INTRODUCTION
Lung cancer is the leading cause of cancer related 
death worldwide with a mean 5 year survival rate of less 
than 15% [1]. 85% of lung cancer is classified as non-
small cell lung carcinoma (NSCLC). The two predominant 
histological subtypes are adenocarcinoma (AD), which 
account for 50% of NSCLC, and squamous cell carcinoma 
(SQ), which account for 40% of NSCLC [2]. AD have 
glandular histology and intracellular mucous production 
and express thyroid transcription factor 1 (TTF1) consistent 
with an origin in the distal lung. By contrast, SQ, which 
arise in more proximal airways, are more reminiscent of 
pseudostratified columnar epithelium of the upper airways 
and are characterized by keratinisation, intercellular 
desmosome formation and expression of p63 [3] and 
p40 [4]. In addition, both entities are characterized by 
a different set of driver mutations. Mutations of the 
oncogenes KRAS (25–40%), EGFR (10–15%), BRAF 
(2–4%), and HER2 (2%), and translocations of ALK (5–
7%) and ROS1 (2%) are found predominantly in AD at 
frequencies indicated in brackets, most of which are targets 
for currently available or potential targeted therapies [5]. 
Potentially targetable driver mutations are less frequent in 
SQ than in AD. These include mutations of the discoid-
containing receptor 2 (DDR2) (3.8%), PTEN (10%) and 
PIK3CA (16%), or amplification of FGFR1 (20%) [6, 7].
Adenosquamous carcinoma (ADSQ) of the lung is 
a rare subtype of NSCLC that accounts for 2–4% of lung 
cancer [8]. This type is characterized by the morphological 
presence of both SQ and AD patterns, each comprising at 
least 10% of the total tumor volume. The two components 
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represent the typical immunoprofile of AD and SQ 
differentiation in the lung, i.e. TTF1 and napsin positivity 
(80% and 58% respectively) for the AD component and 
p63 and CK5/6 positivity (100% and 73% respectively) 
for the SQ component [9]. p40 is considered superior to 
p63 in terms of specificity of classical SQ [4], but whether 
this marker allows for the discrimination of AD and SQ 
components of ADSQ is not well studied. The prognosis 
of ADSQ is generally worse compared to classical AD or 
SQ, independent of the ethnic background [10–12].
ADSQ is a striking example of a morphologically 
dichotomous tumor whose genomic landscape has yet to 
be systematically probed for its contributory role to this 
dichotomy. In classical lung AD, multiregional sequencing 
revealed that the majority of mutations of cancer genes 
were trunk mutations, which represent ubiquitous 
mutations present in all regions of the tumor, and one 
out of 21 mutations within cancer genes was a branch 
mutation [13]. The latter class of mutations represents 
heterogeneous mutations present only in one region of the 
tumor. Intratumoral heterogeneity may have an impact on 
biopsy strategy, as single biopsies may be inadequate for 
identifying all cancer gene mutations. These findings may 
have consequences on treatment planning since important 
drug targets may be missed. The degree of tumor 
heterogeneity correlates with the likelihood of postsurgical 
relapse in patients with localized lung cancer [13].
The aim of this study was to assess tumor 
heterogeneity of ADSQ by a combination of next 
generation sequencing (NGS) using the Cancer hotspot 
panel as well as the Colon and Lung Cancer panel and 
fluorescence in situ (FISH) analysis. To verify mutations 
identified by NGS, tumor cells were collected from AD 
and SQ components by laser capture microdissection and 
analyzed by Sanger sequencing. This allowed us to assess if 
each component harbors a different set of mutations. To our 
knowledge, this is the first comprehensive study assessing 
the mutational status of cancer-related genes in ADSQ.
RESULTS
Patient’s collective
A total of 16 patients diagnosed with adeno-
squamous carcinoma of the lung at the Institutes of 
Pathology in Bern and Locarno were enrolled in this 
analysis. The characteristics of the patients are shown in 
Supplementary Table 1. The mean age was 76 years and 
most patients were male. Thirty percent of tumors showed 
evidence of lymph node metastasis and the majority of 
tumors showed moderately differentiated histology.
Analysis of AD and SQ components of ADSQ
Serial tissue sections from paraffin blocks were 
performed as outlined in Supplementary Figure 1. The 
tumor region encompassing the AD and SQ components 
were defined by histological and immunohistochemical 
criteria. Morphological criteria for the AD component 
were glandular histology and intracellular mucous 
production. Morphological criteria for the SQ component 
were pseudostratified columnar histology, keratinisation 
and formation of intercellular desmosomes (Figure 1A 
and 1B) (see WHO guide lines [1–3]).
Figure 1: Example of an adenosquamous carcinoma tissue sample. Tissue sections encompassing the adenocarcinoma 
component A, C, E. and squamous cell component B, D, F. were stained with H&E (A, B), immunostained with a monoclonal antibody 
against TTF1 (C, D) and immunostained with a monoclonal antibody against p63 (E, F).
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Immunohistochemical staining for Thyroid 
transcription factor 1 (TTF1), a marker specific for AD of 
the lung [9], gave rise to a significantly stronger signal in 
the AD component compared to the SQ component in 13 
out of 16 ADSQ (Table 1 and Figure 1C and 1D). Tumors 
#3, 9 and 10 revealed either no staining or equal staining 
for TTF1 in both components. These tumors were analyzed 
for the expression of napsin, an alternative marker for 
classical AD. All tumors showed high level expression 
of napsin in the AD component, but no expression in the 
SQ component (Table 1). By contrast, all ADSQ samples 
revealed much stronger staining for p63 in the SQ 
component than in the AD component (Table 1 and Figure 
1E and 1F). Consistent with this result, the p40 marker, 
which is considered a more specific marker than p63, 
gave rise to intensive staining of the SQ component but no 
staining of the AD component in 15/16 ADSQ (Table 1). 
In conclusion, all tumors could be clearly classified as 
ADSQ based on immunohistochemical stainings.
Mutational analysis of AD and SQ components 
of ADSQ
In a next step, the mutational profile of each 
component of ADSQ was assessed. To this end, regions 
encompassing AD and SQ components, as indicated by 
immunohistochemical stainings, were macroscopically 
dissected from unstained tissue slides. Regions containing 
> 50% normal lung tissue or inflammatory infiltrates 
were excluded from the analysis. DNA was extracted 
from corresponding regions and subjected to NGS 
using the Cancer Hotspot panel, which covers most of 
the important cancer genes. DNA was also subjected to 
NGS using the Colon and Lung Cancer Research panel, 
which allows the assessment of the mutational status 
of additional genes including DDR2, MAP2K1 and 
FBX7,  which are not covered by the Cancer Hotspot 
panel. Sequence analysis revealed an average number of 
480, 000 mapped reads and an average mean depth of 2, 
000 reads. Variant calling was filtered for nonsynonymous 
SNPs, indels and spliced variants. FFPE material may 
result in false positive low frequency (< 5%) calls owing 
to fixation artifacts. To remove false positive calls, variant 
allele frequency threshold was set to 5%. Common germ-
line mutations that are predicted to have no effect on the 
protein function, as indicated by SIFT/polyphen analysis, 
were also discarded.
Supplementary Table 2 shows all predicted non-
synonymous somatic changes that were identified by 
NGS using the Cancer Hotspot and Colon and Lung 
Cancer panels. A total of 26 somatic mutations were 
identified in 15 out of 16 tumors while one tumor revealed 
no mutation. Among the identified mutations, 3 indel 
mutations, 2 splice-site mutations and 21 nonsynonymous 
SNPs were obtained. Nine out of 26 mutations revealed 
variant read frequencies that were > 3 times higher in one 
component compared to the other component of the same 
tumor sample, suggesting that these mutations are branch 
mutations (Supplementary Table 2). These include TP53 
p.T155I, p.Y126C and p.P190L mutations in samples #4 
and #13, CDKN2A p.W110* mutation in #5,  PIK3CA 
p.E545K mutation in #4 and 10, and RB1 p.G203fs*8 
and PTEN p.Q171* mutations in #16. All other mutations 
seem to be trunk mutations as they gave rise to variant 
read frequencies that were similar in both components.
Although corresponding regions were carefully 
macrodissected, it cannot be excluded that some DNA 
samples may be cross-contaminated by the DNA from 
the other component. To assess this possibility, cells 
were collected by laser capture microdissection from 
each component and analyzed by Sanger sequencing 
for mutations identified by NGS. To assess if identified 
mutations were indeed of somatic origin, normal tissue 
collected from the same patient was also included. There 
was a high agreement between the results obtained by NGS 
and Sanger sequencing: not only were the same mutations 
identified but also the assignment of these mutations to the 
trunk or branches, respectively, was consistent between 
both sequencing methods (Supplementary Table 2).
Somatic mutations identified in this study are 
presented in Figure 2. Our results indicate that mutations 
in the EGFR signaling pathway are among the most 
prominent mutations in ADSQ. Five out of 16 tumors 
harbored bona fide EGFR mutations including a p.E746_
E750 deletion in sample #1 and a p.L858R missense 
mutation in samples # 2, 6, 12 and 16 (Supplementary 
Table 2, Figure 2 and Figure 3A, 3B). These mutations 
confer increased sensitivity to tyrosine kinase inhibitors 
[14, 15]. In each case, the same EGFR mutation was 
detected in both components of the tumor (Figure 2 and 
Figure 3A, 3B) indicating a monoclonal origin of ADSQ. 
Interestingly, EGFR mutations were more prevalent than 
expected for a Caucasian population. By contrast, KRAS 
mutations, which are present in 25–40% of AD [5], were 
not detected in our collective of ADSQ samples.
Mutations in the PI3K signaling pathway are typical 
for SQ [7]. Four ADSQ tumors harbored mutations in the 
PIK3 pathway; one tumor harbored a p.C420R mutation in 
the C2 region and two tumors harbored a p.E545K mutation 
in the helical region of the PIK3CA gene, and one tumor 
harbored a p.Q171* mutation in the PTEN gene. All three 
mutations are predicted to result in constitutive activity of 
the PI3K signaling pathway [16]. In tumor sample #12, the 
same mutation was detected in both components (Figure 
2 and Figure 3C) while tumor samples #4, #10 and #16 
harbored mutations that were only present in one, but not 
the other component (Figure 2 and Figure 3D). Thus ADSQ 
show mutations typical for both classical AD and SQ.
TP53 mutations were also common in our collective of 
ADSQ: 6 out of 16 tumors harbored TP53 mutations, 4 of 
which were trunk mutations while 2 were branch mutations. 
In particular, both components of tumor #4 contained different 
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TP53 mutations. This suggests that TP53 mutations can either 
occur before or after separation of the AD and SQ components 
from a common precursor. Most hotspot mutations of the 
TP53 gene including some of the mutations identified in this 
study are gain of function mutations, which lead to increased 
expression of p53 protein in the tumor tissue [17]. To assess if 
the expression pattern for p53 reflects the mutational profile, 
immunohistochemistry was performed using a monoclonal 
Table 1: Characterization of adenosquamous carcinomas by immunohistochemistry and FISH
Morphological Immunohistochemistry FISH
Tumor classification TTF-1 p63 napsin p40 TP53 ALK ROS1 EGFR
1 AD ++1 – na – + – – –
SQ + ++ na ++ + – – –
2 AD ++ – na – – – – ++
SQ – + na ++ – – – –
3 AD + – ++ – ++ – – –
SQ + ++ – ++ ++ – – –
4 AD + – na – ++ – – –
SQ – ++ na ++ ++ – – –
5 AD ++ + na – + – – –
SQ – ++ na + + – – –
6 AD + – na – + – – –
SQ – ++ na ++ + – – –
7 AD ++ + na – + – – –
SQ – ++ na ++ + – – –
8 AD + + na + ++ – – –
SQ – ++ na ++ ++ – – –
9 AD – – ++ – – – – –
SQ – ++ – ++ – – – –
10 AD – – ++ – + – – –
SQ – ++ – ++ + – – –
11 AD ++ – na – + – – –
SQ – ++ na ++ + – – –
12 AD + – na – + – – –
SQ – ++ na ++ + – – –
13 AD + – na – – – – –
SQ – ++ na ++ ++ – – –
14 AD + – na – – – – –
SQ – ++ na ++ – – – –
15 AD + – na – – – – –
SQ – ++ na – – – – –
16 AD + – na – – – – –
SQ – ++ na ++ ++ – – –
1–, negative; +, weak positive; ++, strong positive or amplified; na, not analyzed
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antibody directed against p53. As shown in Table 1 and Figure 
4A–4D, tumor samples #3, 4, 8, 13 and 16, which contained 
gain of function mutations of the TP53 genes, also showed 
enhanced expression of the p53 protein. Most strikingly, 
tumors #3, 4, 8 and 16 which either contained a TP53 mutation 
in the trunk or independent TP53 mutations in the branches, 
showed enhanced p53 expression in both components while 
tumor #13, which contained a TP53 mutation only in the 
SQ component, showed enhanced expression exclusively 
in this component. In contrast, tumor #9, which contained a 
loss of function mutation of the TP53 gene owing to a A > T 
transversion at the canonical 5′ splice site of exon 6 in both 
components, gave rise to no p53 protein expression (Table 1).
In addition, mutations in cell cycle genes including 
those in Rb and CDKN2A were identified in 3 tumor samples 
(#5, 8 and 16). These mutations are predicted to lead to 
enhanced cell cycle progression of tumor cells. It remains 
to be shown if the p.P1369V missense mutation in the APC 
gene in tumor #3 results in enhanced activity of the β-catenin 
pathway. A G > C transversion at the 5′ splice site of exon 4 
of STK11 was also identified in both components of tumor #5. 
Finally, a p.M541L mutation in the transmembrane domain of 
the KIT gene and a p.V722I mutation in the JAK3 gene were 
identified (samples #7, 14 and 15, Figure 2). These sequence 
alterations have been identified as somatic mutations as well 
as sequence variants occurring in the normal population, 
and it is not clear whether or not these sequence alterations 
may affect protein functions. The mutations identified in our 
collective were clearly somatic mutations as they were not 
present in normal tissue collected from the same patient.
ALK and ROS1 translocations are also important 
oncogenic drivers of NSCLC [5]. Since these genomic 
Figure 2: Mutational landscape of adenosquamous carcinomas. Horizontal phylogenetic trees are shown for all ADSQ analyzed 
in this study. Mutations common to both tumor components are represented by the trunk (AD + SQ, close parallel lines) and mutations only 
found in the AD (blue line) or SQ (green line) component are represented by branches. Individual ADSQ tumors are indicated by numbers.
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alterations cannot be detected by NGS using the Cancer 
hotspot or Colon and Lung Cancer panels, FISH analysis 
was performed. However, no ALK or ROS1 translocation 
was detected in our collective of ADSQ (Table 1). Tumor 
#2 gave rise to EGFR amplification in the AD component, 
but not the SQ component.
Analysis of classifier miR-205 in ADSQ tumor 
samples
MicroRNAs are important regulators of diff eren-
tiation and their expression profile correlates signi-
ficantly with the state of differentiation of various tissues 
[18]. Hence miRNAs proved to be very useful for tumor 
classification [19]. To assess if ADSQ components reflect 
the expression pattern of classical AD and SQ, classifier 
miR-205, which is upregulated in SQ [20], and miR-
21, which is upregulated in both tumor subtypes, were 
analyzed. As shown in Figure 5, miR-21 was expressed 
at similar levels in both components of ADSQ as well 
as in classical AD and SQ. In agreement with published 
results, the expression level of miR-205 was 200 times 
higher in classical SQ than in classical AD (p = 0.05). 
In contrast, no significant difference in the expression 
level was observed between AD and SQ components of 
ADSQ.
Figure 3: Representative electropherograms of EGFR and PIK3CA genes from corresponding AD (upper panel) and 
SQ (lower panel) components. A. EGFR p.E746_E749del deletion in tumor #1. B. EGFR p.L858R mutation in tumor #12. C. PIK3CA 
p.C420R mutation in tumor #12. D. PIK3CA E545K mutation in tumor #10. Mutations in (A–C) are common to both components and the 
mutation in (D) is unique to the SQ component. Asterisks indicate alterations to the wild-type sequence.
Figure 4: Intratumoral heterogeneity of TP53 mutations. Immunohistochemical staining for TP53 of AD component of tumor #4 
harboring a TP53 p.T155I mutation A. corresponding SQ component harboring a TP53 p.Y126C mutation B. AD component of tumor #13 
containing the wild-type sequence C. and corresponding SQ component harboring a TP53 p.P190L mutation D.
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In conclusion, although AD and SQ compo nents 
clearly differ by morphological as well as immuno-
histochemical criteria, they cannot be discriminated 
by means of mutational profiling of cancer genes or by 
expression analysis using classifier miRNAs.
DISCUSSION
Only a few studies exist which assessed the muta-
tional profile of ADSQ [21–25]. In almost all studies 
Asian populations were analyzed, but it is not known 
if this ethnic group may exhibit a different mutational 
profile compared to Caucasian populations. In most cases 
mutational analysis was restricted to EGFR or KRAS. We 
are the first to provide a mutational analysis of ADSQ 
from Caucasian patients using an extended set of cancer-
related genes including those which are frequently mutated 
in classical AD or SQ. All somatic mutations which were 
identified by NGS were confirmed by Sanger sequencing 
in cancer cells collected from each component by laser 
capture microdissection. This approach ensures that there 
is little cross-contamination between ADSQ components 
and therefore allows an unequivocal assignment of 
mutations to either component. In contrast, most other 
studies used macroscopically dissected material, which 
may be potentially cross-contaminated.
We show for the first time that ADSQ harbor driver 
mutations, which are either specific for classical AD or 
Figure 5: Expression analysis of miR-21 (upper panel) and miR-205 (lower panel) in ADSQ components. Expression of 
miR-21 or miR-205 relative to the expression of RNU-48 is shown for classical AD and SQ and for AD and SQ components of ADSQ. The 
difference in the expression of miR-205 between classical AD and SQ was statistically significant (p = 0.05).
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SQ including mutations in EGFR or genes in the PI3K 
pathway. The surprisingly high prevalence of EGFR 
mutations in ADSQ is a key finding of this study. This 
has significant therapeutic implications: small tyrosine 
kinase inhibitors gefitinib and erlotinib are clinically 
effective for the treatment of NSCLC harboring activating 
EGFR mutations [14, 15]. Thus, although ADSQ is more 
aggressive compared to classical AD or SQ [12], more 
patients diagnosed with ADSQ may benefit from targeted 
therapy. In contrast, KRAS mutations were less prevalent 
than expected for a Caucasian population. The finding that 
EGFR was more prevalent and KRAS was less prevalent 
in ADSQ than in classical AD of patients of the Caucasian 
ethnic group suggests that carcinogenesis of ADSQ may 
be more similar between Western and Asian populations 
compared to classical AD. Tochigi et al. [23] reported 
similar EGFR mutation frequencies in classical AD 
and ADSQ within a Caucasian ethnic group which is in 
contrast to our findings. The reason for the discrepancy of 
these results is not clear, but it may either be explained by 
the relatively small cohort of patients used in these studies 
or, alternatively, by the analysis of different cohorts with 
specific risk factors. We show that EGFR mutations are 
present in both components suggesting that patients with 
ADSQ may be accessible to therapy using EGFR tyrosine 
kinase inhibitors. Indeed, several case studies reported 
good therapy responses of patients with ADSQ to EGFR 
inhibitors [24].
In addition to EGFR mutations, we observed a high 
incidence of mutations in genes of the PI3K signaling 
pathway, some of which were trunk mutations and 
some were branch mutations occurring in the AD or SQ 
component. Preclinical studies suggested that patients 
with PIK3CA or PTEN mutations may benefit from pan-
class I PI3K inhibitors [26, 27]. In addition, lung cancer 
cell lines harboring PIK3CA or PTEN mutations were 
sensitive to dual PIK3CA/mTOR inhibitors [28, 29], which 
raises the hope that patients with mutations in the PI3K 
pathway may benefit from this type of targeted therapy 
in the future. Introduction of activating PIK3CA mutants 
into EGFR mutant cell lines conferred resistance to EGFR 
inhibitors [29]. Based on these results we may conclude 
that patient #12, who contains an EGFR L858R mutation 
as well as a PIK3CA C420R mutation in the tumor DNA, 
may be less responsive to EGFR or PIK3CA inhibitors, 
but this has not yet been confirmed by clinical studies. It is 
possible, however, that this patient may benefit from new 
combinations of targeted drugs.
Our results indicate that driver mutations were 
normally in the trunk. This suggests that ADSQ are of 
monoclonal origin, which is in agreement with findings 
obtained by others [22, 23, 25, 30–32] and which may 
also be true for other heterogeneous lung tumors [31]. 
The molecular results support the histopathologist 
historical “morphology only” view of ADSQ being a 
real entity fitting in the “lung heterogeneity concept” 
[33, 34]. Mather et al. [35] reported the isolation of cancer 
stem like cells from human ADSQ that recapitulated 
all features of ADSQ in mouse xenograft experiments, 
consistent with a monoclonal origin of ADSQ. However, 
the molecular mechanism of (trans)-differentiation into 
AD or SQ components is not clear. Loss of STK11 or 
targeted deletion of PTEN or TGFβR1 in the oncogenic 
KRASG12D mouse model gave rise to ADSQ-like tumors 
[36]. Emerging tumors initially showed AD histology 
and expressed AD-specific markers, but STK11-deficient 
lung AD progressively transdifferentiated to SQ [37], 
suggesting that ADSQ are a transitional state between 
AD to SQ differentiation. Conversely, expression of 
SQ-related antigen in the AD component of ADSQ was 
higher while Mucin1 was lower than in classical AD 
suggesting a transition from SQ to AD [38]. Our findings 
that ADSQ can harbor mutations typically found in 
AD or SQ, respectively, may suggest that ADSQ have 
developed either from an AD-like or SQ-like precursor 
cell. Five ADSQ tumors (#1, 2, 6, 12 and 16) harbored 
EGFR mutations suggesting a transition from AD to SQ. 
In contrast, tumors #4, 10 and 16 harbored a PIK3CA/
PTEN mutation in the SQ branch suggesting that 
acquisition of this mutation induced the transition into 
the SQ component. Expression of classifier miR-205 in 
the AD and SQ components of ADSQ was intermediate 
between that of classical AD and SQ consistent with the 
finding that ADSQ is a transitional state between classical 
AD and SQ, but this possibility has to be confirmed by 
extended miRNA expression profiling or methylation 
analysis. By contrast, both components of ADSQ also 
clearly show hallmarks of classical AD or SQ as indicated 
by histomorphological criteria as well as expression of 
TTF1, napsin, p63 or p40.
Multiregional sequencing of classical AD revealed 
that only 1 out of 21 cancer genes were in the branch, 
while all other mutations were trunk mutations [13]. In 
contrast, our study revealed that one out of four mutations 
was a branch mutation. In particular, TP53 mutations were 
often identified as branch mutations. These results indicate 
that separation of AD and SQ components may have 
occurred very early during the development of ADSQ. 
The fact that ADSQ reveals a high incidence of branch 
mutations, makes it an attractive model for studying tumor 
heterogeneity.
In conclusion, we show that ADSQ harbors driver 
mutations specific for both classical AD and SQ. Owing 
to the high prevalence of these mutations, a higher 
proportion of patients may benefit form targeted therapy 
than expected for a Caucasian population. In addition, 
our results have diagnostic implications, especially in 
advanced tumors which are not resected and where only 
small biopsies are available for molecular testing: since 
the most relevant targetable driver mutations are mainly 
found in the trunk, they may not be missed by mutational 
analysis in such specimens. However, a problem that 
arises using small biopsies is that ADSQ can present as SQ 
if the AD component is missed. Consequently molecular 
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testing for the most important drugable targets in AD like 
EGFR, ALK or ROS1 will not be performed, leaving the 
patient without this therapeutic option. Nevertheless, this 
issue may become less relevant in the future, when all 
NSCLC patients are analyzed by NGS.
MATERIALS AND METHODS
Patients and samples
The ethical boards of the Inselspital Bern and the 
institute of Pathology of Locarno have approved the study 
as part of the general approval for research on formalin 
fixed paraffin embedded tissue (KEK Nr. 200/2014). 
Using the full text research tool of our database software 
(Pathowin +), we selected 35 cases of adenosquamous 
carcinoma patients diagnosed in 1993–2007. All cases 
were re-reviewed by two experienced pathologists for 
confirmation of tumor histology following the guidelines 
of the WHO 2004 classification [2]. After review of the 
histological slides 16 cases of operation specimens were 
selected for the study. Nineteen cases were excluded 
due to pretreatment, extensive necrosis or ambiguous 
immunohistochemical staining.
Serial tissue sectioning, laser capture 
microdissection and nucleic acid extraction
Serial 3–6 μm tissue sections were performed from 
paraffin blocks as outlined in Supplementary Figure 1. AD 
and SQ components of each tumor were macroscopically 
dissected for DNA and RNA extraction using the 
QIAamp DNA Micro Kit (QIAGEN) and RecoverALL 
Total Nucleic Acid Isolation kit (Ambion), respectively, 
following the manufacturer’s instructions. Methylol 
groups that are covalently bound to nucleic acids during 
formalin treatment were cleaved from nucleic acids as 
described [39].
Laser capture microdissection was performed 
on 6 μm sections on Polyethylene Naphthalate (PEN)-
membrane slides [39]. Sections were deparaffinized and 
stained with cresyl violet following the manufacturer’s 
instruction (Zeiss). Approximately 1000 tumor cells for 
each component were captured onto an adhesive cap using 
a PALM Microbeam (PALM, Zeiss). DNA was extracted 
from the dissected material as described above.
Immunohistochemistry
Three μm formalin-fixed, paraffin-embedded 
sections were immunostained for TTF1 (Abcam, clone 
2Cla, 1:50, pretreated with citrate buffer for 20 min 
at 100°C), p63 (Leica-Novocastra, clone 7 Jul, 1:40, 
pretreated with bond 2 for 30 min at 100°C), napsin 
(Leica-Novocastra, clone IP64, 1:400, pretreated with 
bond 2 for 30 min at 95°C), p40 (Biocare Medical, 
polyclonal antibody, 1:100) and TP53 (Dako, clone DO-7, 
1:200, pretreated with bond 2 for 20 min at 95°C) using 
a Bond Max autostainer (LEICA Bond III platform) 
from Leica Microsystems (Wetzlar, Germany) and 
counterstained with haematoxylin. Mouse IgG1 (Dako, 
1:20) was used as a negative control.
Fluorescence in-situ hybridization
The gene status of ALK (Vysis LSI ALK Dual Color, 
break apart rearrangement probe, Abbott Molecular, Des 
Plaines, IL, USA), ROS1 (ZytoLight SPEC ROS1 Dual 
Color Break Apart Probe, Zytovision, Bremerhaven, 
Germany) and EGFR (Vysis LSI EGFR spectrumOrange/
CEP7 spectrumGreen Probe, Abbott Molecular) were 
evaluated using commercially available FISH probes. 
2–3 μm tissue sections were deparaffinized and pretreated 
using the commercial pretreatment kit Vysis (Abbott 
Molecular) and hybridized with the probe overnight 
in a humidified chamber at 37°C. Post hybridisation 
washes were performed using the Pathvysion kit (Abbott 
Molecular) and counterstained with DAPI. Thresholds for 
a positive signal constellation for the ALK or ROS1 probes 
were set to 15%. Threshold for a positive EGFR signal, 
as indicated by an EGFR to CEP7 ratio > 2.0, was set to 
10%. At least 60 cells were counted.
Library preparation and semiconductor 
sequencing
For library preparation, multiplex PCR was 
performed using the Ion Ampliseq Cancer Hotspot Panel 
v2 (Life Technologies, Zug). This panel consists of a single 
pool of 207 primer pairs and results in the amplification of 
the following genes: ABL1, EZH2, JAK3, PTEN, AKT1, 
FBXW7, IDH2, PTPN11, ALK, FGFR1, KDR, RB1, APC, 
FGFR2, KIT, RET, ATM, FGFR3, KRAS, SMAD4, BRAF, 
FLT3, MET, SMARCB1, CDH1, GNA11, MLH1, SMO, 
CDKN2A, GNAS, MPL, SRC, CSF1R, GNAQ, NOTCH1, 
STK11, CTNNB1, HNF1A, NPM1, TP53, EGFR, HRAS, 
NRAS, VHL, ERBB2, IDH1, PDGFRA, ERBB4, JAK2 and 
PIK3CA. Multiplex PCR was also performed using the 
Ion AmpliSeq Colon and Lung Cancer Research Panel v2. 
This panel consists of a single pool of 92 pairs of primers 
and covers some of the genes of the Cancer Hotspot 
panel as well as some additional genes including DDR2, 
MAPK1 and FBX7. Library preparation was performed 
using 10 ng of DNA according to the manufacturer’s 
recommendations. The obtained DNA fragments were 
digested with FuPa followed by ligation of barcoded 
sequencing adaptors (Ion Xpress barcode adapters 1–16, 
Life Technologies) and purified using AMPure XP 
magnetic beads (Beckman Coulter, Nyon) according to 
the manufacturer’s instructions.
Libraries were diluted to 1.2 ng/mL. 4 libraries 
of the Cancer Hotspot panel or 8 libraries of the Colon 
and Lung Cancer Research were pooled and subjected to 
emulsion PCR using the Ion OneTouch 200 bp kit (Life 
Oncotarget23914www.impactjournals.com/oncotarget
Technologies). After enrichment (Ion OneTouch ES), the 
library was sequenced using the Ion Torrent 200 bp kit (Life 
Technologies). Sequence analysis was performed on an Ion 
316 chip v2 using an Ion Torrent PGM (Life Technologies). 
The average number of mapped reads was 480, 000 (range 
323, 000–672, 000), the percentage of reads that were aligned 
over a target region was 96% (94–97%), the average mean 
depth was 2, 000 (1, 000–3, 200) and the average uniformity 
was 98% (95–100%). The average target base coverage at 
100x was 99.4% (98–100%).
Raw data analysis was performed using the Ion 
Torrent Suite software 4.2 relative to the human reference 
sequence (hg19). For variant calling (v4.2.1.0) somatic 
low stringency configuration was used. Detection of 
single nucleotide polymorphisms or indel polymorphisms 
was performed using the Torrent Reporter 4.2 and the 
AmpliSeq CHPv2 single sample workflow. Alternatively, 
sequence alignment and variant detection was performed 
using the CLC Cancer Research Workbench version 1.5.2. 
Variant allele frequency threshold was set to 5%. Identified 
mutations were visually inspected using the IGV software.
Sanger sequencing
Mutations identified by semiconductor sequencing 
were confirmed by Sanger Sequencing. To this end, DNA 
was extracted from laser capture microdissected material 
and amplified by PCR in a total volume of 30 μl containing 
0.5 μM of the same primer pair as was used for library 
preparation for NGS and 1 Unit Hot Start Taq Polymerase 
(Qiagen) with an initial hold stage at 95°C for 10 minutes 
followed by 40 cycles of 94°C, 60°C and 72°C for 1 
minute each. The sequence of the primers is available at 
the homepage from Life Technologies. PCR products were 
purified using the ExoSap-IT cleanup kit (Affymetrix) and 
subjected to sequencing using the Big Dye Terminator v1. 
1 cycle sequencing kit (Applied Biosystems). Sequencing 
products were purified using the Big Dye x-Terminator 
purification kit (Applied Biosystems) and analysed 
using the Genetic Analyzer 3500 (Applied Biosystems). 
Sequence analysis was performed using the Sequencing 
Analysis Software 5.4 (Applied Biosystems).
Real-time PCR
Real-time PCR was performed as described [39]. 
Quantitative PCR was carried out using TaqMan assay 
(Applied Biosystems) and the One-step PCR system 
(Applied Biosystems). The mean CT was determined from 
triplicate experiments. miRNA levels were normalized to 
the level obtained for RNU48. Changes in expression were 
calculated using the ΔΔCT method.
Statistics
Statistical analyzes were performed using the 
GraphPAD prism software. Statistical differences were 
calculated using unpaired two-tailed Student’s t test. A 
probability of p ≤ 0.05 was considered statistically significant.
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